Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma

 

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

Read more

Stopping and starting cancer cell cycle weakens and defeats multiple myeloma

 

Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.

Read more

New drug strategy attacks resistant leukemia and lymphoma

Scientists at the Dana-Farber/Children’s Hospital Cancer Center have developed an anti-cancer peptide that overcomes the stubborn resistance to chemotherapy and radiation often encountered in certain blood cancers when the disease recurs following initial treatment.

Read more

Researchers make promising discovery in pursuit of effective lymphoma treatments

Researchers at NYU School of Medicine have identified a target for slowing the progression of multiple myeloma by using currently available drugs.

Published recently in Nature Cell Biology, the study reveals a pathway that, if deactivated, may help slow the development of the disease.

Read more

New compound targets key mechanism behind lymphoma

Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3.

Read more

Researchers develop first ‘theranostic’ treatment for acute lymphoblastic leukemia (ALL)

A team of researchers at Case Western Reserve University School of Medicine has developed the first “theranostic” agent for the treatment of acute lymphoblastic leukemia (ALL). ALL is the most common type of childhood cancer diagnosed in approximately 5,000 new cases each year in the United States. The findings provide insight into pediatric oncology that specifically focuses on the development of “theranostic” agents– a treatment platform that combines a selective diagnostic test with targeted therapy based on the test results.

Read more

Emerging lymphoma and myeloma treatments focus on improving individual patient response

Lymphoma and myeloma are both malignant diseases that arise from lymphocytes, a subset of blood cells, and commonly involve lymph nodes and the bone marrow. Although considerable progress has been made in the treatment of these diseases, they remain a significant challenge for patients and their hematologists. New research introducing unique treatment approaches and targets for lymphoma and myeloma will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

Read more

USC microbiologists identify two molecules that kill lymphoma cells in mice

Researchers at the University of Southern California have identified two molecules that may be more effective cancer killers than are currently available on the market.

The peptides, molecules derived from a cancer-causing virus, target an enzyme in cancerous cells that regulates a widely researched tumor suppressor protein known as p53. The peptides inhibit the enzyme, causing p53 levels in cancer cells to rise, which leads to cell death. Lymphoma tumors in mice injected with the two peptides showed marked regression with no significant weight-loss or gross abnormalities.

Read more

Berkeley Lab scientists find that normal breast cells help kill cancer cells

It is well known that the human body has a highly developed immune system to detect and destroy invading pathogens and tumor cells. Now, researchers at the U.S. Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) have shown that the body has a second line of defense against cancer – healthy cells. A new study shows that normal mammary epithelial cells, as they are developing, secrete interleukin 25, a protein known for its role in the immune system’s response to inflammation, for the express purpose of killing nearby breast cancer cells.

Read more

Scripps Research and MIT scientists discover class of potent anti-cancer compounds

LA JOLLA, CA, AND JUPITER, FL – March 7, 2011 – Embargoed by the journal PNAS until March 7, 2011, 3 PM, Eastern time –Working as part of a public program to screen compounds to find potential medicines and other biologically useful molecules, scientists from The Scripps Research Institute and Massachusetts Institute of Technology (MIT) have discovered an extremely potent class of potential anti-cancer and anti-neurodegenerative disorder compounds. The scientists hope their findings will one day lead to new therapies for cancer and Alzheimer’s disease patients.

Read more

Next Page »